Brief: Terns Pharmaceuticals Q4 Net Income USD -21.019 Million
14/03/2024 20:05
Mar 14 (Reuters) - Terns Pharmaceuticals Q4 operating expenses USD 24.058 million. * Q4 basic EPS USD -0.29 * Q4 income from operations USD -24.058 million * Q4 pretax profit USD -20.97 million
Recent news on Terns Pharmaceuticals
See all newsNASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP-East West Bancorp, Reliance, S&P Global
Brief: Merck Announces Expiration Of Hart-Scott-Rodino Act Waiting Period To Acquire Terns Pharmaceuticals
Brief: Merck Begins Tender Offer To Acquire Terns Pharmaceuticals, Inc.